Form 4: Elanco CEO Jeffrey Simmons Boosts Stake with Deferred Stock Unit Acquisition

Elanco Animal Health Inc.'s President, CEO, and Director, Jeffrey N. Simmons, has acquired 200.5243 deferred stock units, increasing his beneficial ownership.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc. (ELAN), acquired 200.5243 Deferred Stock Units (DSUs) on June 13, 2025.
• Each DSU represents the right to receive one share of Elanco common stock or its cash equivalent.
• The acquisition price per DSU was $13.81.
• Following this transaction, Mr. Simmons beneficially owns a total of 16,655.6629 DSUs.
• These DSUs are set to settle in cash or shares upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The acquisition of deferred stock units by the CEO is generally a positive signal, indicating alignment of interests and confidence in the company. It's not a direct purchase of shares on the open market, but rather a compensation-related acquisition, which is a routine positive.

Positives

• The acquisition of additional deferred stock units by the CEO indicates continued alignment of management's interests with shareholder value.
• The increase in beneficial ownership by a key executive can be viewed as a positive signal regarding their confidence in the company's future performance.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing, detailing an executive's acquisition of deferred stock units, is a routine disclosure of insider ownership changes. It does not provide specific industry context or competitive analysis, but generally, such transactions reflect standard executive compensation practices within the animal health industry.

Comparison to Industry Standards

• This Form 4 filing is a standard disclosure of executive compensation in the form of deferred stock units.
• The specific details of the compensation plan (Executive Deferral and Stock Match Plan) are typical for publicly traded companies, aligning executive incentives with long-term company performance.
• Direct comparisons to specific comparable companies or projects are not provided within this filing, as it focuses solely on the individual transaction.

Corporate Governance

Related Party Transactions

• The reported transaction is an acquisition of deferred stock units by a key executive (Jeffrey N. Simmons), which is a related party transaction inherent to executive compensation. No other related party dealings are disclosed in this specific filing.

Stakeholder Impact

• Shareholders: The acquisition of deferred stock units by the CEO aligns his interests with shareholders, potentially signaling confidence in the company's future.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Elanco Animal Health Inc., ELAN, Jeffrey N Simmons, Deferred Stock Units, DSU, Insider Transaction, SEC Form 4, Executive Compensation, Stock Ownership